Article

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Three women on a Zoom call discussing tracking side effects during breast cancer treatment.
Three women on a Zoom call discussing managing side effects of breast cancer treatment.
Three women on a Zoom call discussing managing side effects during breast cancer treatment.
Three women on a Zoom call discussing effective care team communication in breast cancer.
Three women on a Zoom call discussing effective care team communication in breast cancer.
Related Content
Image of doctor and patient.
November 17th 2024

Nurse Champions of Patient Safety, Dignity and Leadership

Erin Longstreth-Papsun, M.S.N., RN, OCN Jeremy Moore Christina Passio, MSN, RN, NE-BC
Three nurses—Maria Hicinbothem, Wandaris Ortiz, and Sandi Wetherbee—are being celebrated for their exceptional dedication to patient care, safety and advocacy.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of a pair of hands holding a paper cut out of a family.
November 16th 2024

I’ve Decided What My Legacy Is During Colon Cancer

Lauryn Cooney
When I was diagnosed with colon cancer, I had a hard time deciding what my legacy should be, but once I realized what it was, I had to keep working hard for it.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.
Illustration of lungs.
November 15th 2024

Anti-TIGIT Therapy-Based Treatment Combo Did Not Improve Survival in Extensive-Stage SCLC

Caroline Seymour
The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.